Shanghai Medicilon Inc (688202) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Medicilon Inc (688202) has a cash flow conversion efficiency ratio of -0.010x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-17.10 Million ≈ $-2.50 Million USD) by net assets (CN¥1.74 Billion ≈ $254.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Medicilon Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Shanghai Medicilon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 688202 current and long-term liabilities for a breakdown of total debt and financial obligations.
Shanghai Medicilon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Medicilon Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SINOPEC Engineering (Group) Co. Ltd
F:1NS
|
-0.016x |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
N/A |
|
VIX Securities JSC
VN:VIX
|
0.012x |
|
Pan Jit International Inc
TW:2481
|
-0.010x |
|
Genusplus Group Ltd
AU:GNP
|
0.609x |
|
LianChuang Electronic Technology Co Ltd
SHE:002036
|
0.001x |
|
Foschini Group Ltd
JSE:TFG
|
0.239x |
|
Beijing VRV Software Corp Ltd
SHE:300352
|
0.012x |
Annual Cash Flow Conversion Efficiency for Shanghai Medicilon Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Medicilon Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 688202 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.14 Billion ≈ $313.17 Million |
CN¥-22.75 Million ≈ $-3.33 Million |
-0.011x | -180.10% |
| 2023-12-31 | CN¥2.51 Billion ≈ $367.41 Million |
CN¥33.32 Million ≈ $4.88 Million |
0.013x | +199.71% |
| 2022-12-31 | CN¥1.60 Billion ≈ $234.54 Million |
CN¥-21.33 Million ≈ $-3.12 Million |
-0.013x | -103.90% |
| 2021-12-31 | CN¥1.33 Billion ≈ $194.26 Million |
CN¥452.94 Million ≈ $66.28 Million |
0.341x | +86.49% |
| 2020-12-31 | CN¥1.14 Billion ≈ $166.18 Million |
CN¥207.77 Million ≈ $30.40 Million |
0.183x | +214.00% |
| 2019-12-31 | CN¥1.00 Billion ≈ $146.42 Million |
CN¥58.30 Million ≈ $8.53 Million |
0.058x | -71.49% |
| 2018-12-31 | CN¥347.89 Million ≈ $50.91 Million |
CN¥71.11 Million ≈ $10.41 Million |
0.204x | -21.38% |
| 2017-12-31 | CN¥287.32 Million ≈ $42.04 Million |
CN¥74.70 Million ≈ $10.93 Million |
0.260x | +87.44% |
| 2016-12-31 | CN¥246.09 Million ≈ $36.01 Million |
CN¥34.13 Million ≈ $4.99 Million |
0.139x | -- |
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in … Read more